Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
SAN FRANCISCO, Feb. 01, 2017 -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced that it will release financial results for the fourth quarter and 2016 after the close of trading on Wednesday, February 15, 2017. The company’s management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.
Investors interested in listening to the conference call may do so by dialing (844) 348-0016 for domestic callers or (213) 358-0876 for international callers, using Conference ID: 58707805. A live and archived webcast of the event will be available on the “Investor Relations” section of the company’s website at: www.irhythmtech.com.
About iRhythm Technologies, Inc.
iRhythm is a commercial-stage digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients. The company’s platform, the Zio Service, has been provided to over 600,000 patients, accumulating more than 150 million hours of curated heartbeat data within iRhythm’s data repository.
Investor Relations Contact: Lynn Pieper Lewis or Leigh Salvo (415) 937-5404 [email protected] Media Contact Aaron Murphy (415) 229-3331 [email protected]
